Integrating Biomarker-Targeted Therapies in the Evolving Metastatic Colorectal Cancer Landscape

Dr. Saeed and Dr. Ahn address how zanzalintinib plus atezolizumab fits alongside the expanding array of biomarker-targeted therapies in metastatic colorectal cancer. Dr. Saeed states that precision medicine approaches should take priority for eligible patients, including those with HER2 amplification, BRAF V600E mutation, KRAS G12C mutation, or RAS wild-type disease amenable to anti-EGFR rechallenge, before applying a biomarker-agnostic strategy. Both discussants note that many of these targeted therapies are being investigated in earlier lines of therapy and may shift to frontline or second line use within the next several years, which would preserve the third-line space as the primary setting for approaches such as zanzalintinib plus atezolizumab. Dr. Ahn highlights several ongoing trials, including studies of trastuzumab-based combinations, BRAF-directed therapy with immunotherapy, and adagrasib with cetuximab, underscoring how rapidly the treatment paradigm is evolving and how these changes may reshape sequencing decisions in the near term.